Loading
VB
Vyant Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 29 Dec 2021.
Vyant Bio, Inc.: what insiders have been doing
Vyant Bio, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Vyant Bio, Inc. The previous disclosure was published on 27 February 2023.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
55
Thresholds
n/a
Buy Volume
€230,994
18 ops. · all time
Sell Volume
€128
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$573.4k
Gross profitUS$2.1M360% margin
Net income-US$19.5M-3406.9% margin
Last declaration on 27 February 2023
Declarations55 total
6,783 shares0Common Stock, $0.0001 par valueSEC:0001493152-23-006131:0
5,712 sharesCommon Stock, $0.0001 par valueSEC:0001493152-23-001918:0
4,032 sharesCommon Stock, $0.0001 par valueSEC:0001493152-23-001920:0
7,526 sharesCommon Stock, $0.0001 par valueSEC:0001493152-23-001915:0
4,368 sharesCommon Stock, $0.0001 par valueSEC:0001493152-23-001919:0
99 shares@ US$1.34011.4% of flowCommon Stock, $0.0001 par valueSEC:0001493152-22-033340:0
8,290 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-028715:0
10,841 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-028717:0
14,285 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-028718:0
7,653 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-028716:0
6,141 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-020760:0
4,696 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-020756:0
4,335 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-020751:0
8,092 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-020766:0
7,281 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-010472:0
3,944 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-010476:0
6,796 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-010480:0
3,640 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-010478:0
5,157 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-010475:0
24,844 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-009831:0
43,478 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-008834:0
43,478 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-008830:0
43,478 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-008835:0
43,478 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-008832:0
43,478 sharesCommon Stock, $0.0001 par valueSEC:0001493152-22-008833:0
25 of 55 declarations
About Vyant Bio, Inc.
Vyant Bio, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker VYNT. The company’s current corporate identity emerged in March 2021, when Cancer Genetics, Inc. completed a merger with StemoniX and was renamed Vyant Bio, Inc. The transaction repositioned the business toward biotechnology-enabled drug discovery rather than a traditional clinical-stage drug development model. Its principal operating footprint has been associated with Cherry Hill, New Jersey, reflecting a U.S. East Coast headquarters base. ([nasdaq.com](https://www.nasdaq.com/press-release/cancer-genetics-and-stemonix-announce-merger-closing-2021-03-31?utm_source=openai))
Vyant Bio was built around two main operating assets: StemoniX and vivoPharm. StemoniX focused on high-density human iPSC-derived screening platforms, especially neural and cardiac models, designed to improve the predictability of preclinical research and support compound screening, disease modeling, and translational discovery work. vivoPharm contributed preclinical development capabilities and contract research expertise. Together, these businesses positioned Vyant Bio as a technology-enabled discovery platform serving biopharma partners and internal research programs. The company’s scientific emphasis was historically centered on neurology, oncology, and adjacent therapeutic areas where better translational tools can reduce development risk. ([nasdaq.com](https://www.nasdaq.com/press-release/cancer-genetics-and-stemonix-announce-merger-closing-2021-03-31?utm_source=openai))
Read moreShow less
From a competitive standpoint, Vyant Bio differentiated itself by combining human biology-based models, screening infrastructure, and preclinical services rather than by building a conventional commercial therapeutics portfolio. That positioned the company against contract research organizations, cell-model developers, and drug-discovery platform companies competing on data quality, biological relevance, and speed. For investors, however, the most important point is that the company’s profile has changed materially. In November 2023, Vyant Bio disclosed that it was in winddown mode following the sale of substantially all of its assets and that it expected to pursue dissolution, with any shareholder value dependent on final liquidation proceeds. ([nasdaq.com](https://www.nasdaq.com/press-release/vyant-bio-provides-update-on-winddown-activities-2023-11-10?utm_source=openai))
As a result, recent developments are primarily about restructuring, asset monetization, and corporate exit rather than product launch or commercial expansion. The company’s public-market relevance now lies more in the liquidation process, governance actions, and SEC Form 4 insider transactions than in an active operating growth story. For French-speaking investors evaluating U.S. listed small caps, Vyant Bio should therefore be viewed as an NASDAQ-listed United States biotech whose original drug-discovery platform model has been overtaken by a winddown and dissolution process. ([nasdaq.com](https://www.nasdaq.com/press-release/vyant-bio-provides-update-on-winddown-activities-2023-11-10?utm_source=openai))
